SMS Pharmaceuticals Posts Consistent Growth as API Portfolio Drives Revenue Up 6% YoY
SMS Pharmaceuticals Limited, a diversified and integrated pharmaceutical company specializing in Active Pharmaceutical Ingredients (API) and complex Intermediates, reported unaudited financial results for the quarter ending June 30, 2026. The company demonstrated broad-based growth across its high-value API portfolio while maintaining strong margins.The Executive Director, P. Vamsi Krishna, stated that FY27 commenced strongly with diversified growth in the high-value API sector and an EBITDA margin sustained at approximately 20%. This performance was attributed to backward integration and an improving product mix, which reinforced structural improvements in unit economics.
Despite structural margin improvements, management noted that EBITDA margins were impacted by planned annual employee increments and elevated freight costs arising from the geopolitical situation in West Asia. The company expects these temporary headwinds to lessen in the near future, supporting further margin expansion.
Financial Performance Snapshot
The results showcase stability across key metrics for Q1FY27 (Q1). Revenue from operations grew 6% year-over-year (YoY), reaching ₹207.0 crore. Gross profit increased by 12% YoY to ₹74.9 crore, resulting in a gross margin of 36%, up 217 basis points (bps) compared to Q1FY26.The company's profitability continued to rise: EBITDA grew 4% YoY to ₹40.95 crore, maintaining a solid 20% margin. PAT increased by 8% YoY, reaching ₹20.20 crore, with the PAT margin holding steady at 10%. The net profit after tax and share of profit from associate was reported at ₹20.91 crore.
A summary of the key financial performance across various periods is detailed below:
| Particulars | Q1FY27 | Q1FY26 | YoY Growth (%) |
|---|---|---|---|
| Revenue from operations | 207.0 Cr | 196.1 Cr | 6% |
| Gross profit (Incl. manufacturing expenses) | 74.9 Cr | 66.7 Cr | 12% |
| Gross profit margin | 36% | 34% | 217bps |
| EBITDA | 40.95 Cr | 39.37 Cr | 4% |
| EBITDA margin | 20% | 20% | -30bps |
| PAT | 20.20 Cr | 18.72 Cr | 8% |
Strategic Investments and R&D Pipeline
SMS Pharmaceuticals is significantly advancing its R&D capabilities and capital expenditure plans. The company completed four DMF/CEP filings during the quarter, placing it on track to meet the FY27 target of 10 filings.The Capex programme stands at ₹280 crore; out of this amount, ₹120 crore has been completed, with the remaining ₹160 crore expected to be finalized by FY27. This investment is crucial for supporting the commercialization of new niche and high-value molecules.
Furthermore, a board approval was given for an infusion of up to ₹50 crore as a loan into its subsidiary, SMS Peptides Private Limited. This move builds upon the initial ₹8 crore investment made in FY26 to establish the company's dedicated peptide R&D facility. The R&D team strength has been enhanced to 200 staff members, bolstering the pipeline of niche and high-value APIs and peptides.
Revenue by Therapeutic Area
The Q1FY27 revenue stream was highly diversified, with strong performance noted across several segments:| Particulars | Q1FY27 (₹ Cr) | % of Total Revenue | YoY Growth (%) |
|---|---|---|---|
| Anti-diabetic | 20.08 | 10% | -69% |
| Anti Retro Viral (ARV) | 65.22 | 32% | 69% |
| Anti-inflammatory | 46.91 | 23% | 4% |
| Anti-migraine | 24.79 | 12% | 44% |
| Anti-ulcer | 10.11 | 5% | -10% |
| Anti-erectile dysfunction | 9.87 | 5% | 262% |
| Anti-epileptic | 11.61 | 6% | 51% |
| Anti-anginal | 11.88 | 6% | 129% |
Future Outlook
Management expressed confidence in achieving the FY27 growth guidance, targeting a sustained EBITDA margin of 20%. This outlook is supported by the upcoming capacity expansion, which will facilitate the commercialization of new niche and high-value molecules. Robust portfolio diversification and expected volume growth from the expanded ARV and anti-inflammatory products are key pillars supporting the revenue trajectory for FY27.SMS Pharmaceuticals Limited has been operating since 1990 and operates two state-of-the-art manufacturing facilities in Hyderabad (200 KL capacity) and Vizag (3,000 KL capacity). The company serves a global customer base in over 70 countries.
SMSPHARMA Stock Price Movement
Shares of SMS Pharmaceuticals Limited on Friday slipped by 0.04% to close at ₹373.9, continuing a slight downturn from the previous trading session. The equity traded a volume of 239,593 shares during the day, falling within an intraday range between ₹365.4 and ₹384.8.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.
Last edited by a moderator: